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CHAPTER 1 
Bacteremia, sepsis, and their current diagnostic and treatment methods 
 
1.1. Bacteremia and sepsis 
Bacterial infections are common in all demographics and are present globally. In 
immunonormal cases, the infection is typically limited to a local site and is effectively 
suppressed by the immune system. However, with an impaired immune response, free bacteria 
can circulate in the bloodstream, resulting in bacteremia. From there, the infection can colonize 
other tissues. The abnormal immune response to these distributed bacteria or their toxins can 
result in life-threatening organ dysfunction, which is known as bacterial sepsis [1]–[3]. If not 
properly treated, sepsis can quickly progress into severe sepsis, septic shock, or death. Even after 
treatment, long-term outcomes include recidivism, recurrent or persistent organ dysfunction, or 
cognitive and functional impairment [4], [5].  
In the United States, more than a million cases of severe sepsis are diagnosed annually [6]. 
With a mortality estimated between 28 and 50 percent [7], [8], severe sepsis is the tenth leading 
cause of death [8], exceeding the number of deaths from prostate cancer, breast cancer, and 
AIDS combined [9]. Furthermore, the incidence of sepsis is increasing in excess of population 
growth in developed countries [8]. Immunocompromised patients are especially susceptible to 
sepsis including the elderly, neonates, and hospitalized patients. Approximately half of severe 
sepsis cases occur in patients already in the ICU [10], and these infections are eight times as 
likely to result in death when compared with other diagnoses [6], incurring additional annual 
healthcare costs of more than $17 billion [7]. 
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1.2. Diagnostic methods 
Beyond the simple definition, there is no single definitive diagnosis for bacterial sepsis [2]. 
Symptoms resultant from an immune response are heterogeneous across patients and can range 
from fever or hypothermia, leukocytosis or leukopenia, tachycardia, and hypotension, none of 
which are unique to sepsis [2]. Certain innate biomarkers can be used as part of diagnosis, such 
as elevated lactate levels, inflammatory cytokines, C-reactive proteins, and procalcitonin, but 
these cannot differentiate between pathogen genera or species and primarily serve as a means of 
ruling out infection rather than confirmation of infection [9], [11], [12]. The only clinical means 
of determining the origin of sepsis – and thus the treatment – is the confirmation and 
identification of pathogens.  
The “gold-standard” for pathogen identification is through blood culture [13]. Blood 
samples are aliquoted and cultured on selective media and incubated, enabling biological 
amplification and isolation of the pathogen. Some automation can be achieved by detecting 
growth via changes in partial pressures of gasses or changes in turbidity of liquid media. 
Differential staining (e.g., Gram staining) and other biochemical assays can also be used to 
classify the pathogen. However, these techniques are reliant on culturing, which require 
overnight incubation or longer, delaying effective treatment from being administered. 
Additionally, identification using these methods requires a technician, making pathogen 
identification outside of a hospital setting difficult. More sophisticated techniques such as 
polymerase chain reaction (PCR) and mass spectroscopy are being developed, but also currently 
suffer from the need for pathogen amplification and isolation to generate a bacteria-specific 
signal of sufficient quality to distinguish in comparison with the background of uninfected whole 
blood [14].   
 3
 
1.3. Treatment methods 
Effective treatment of bacteremia involves elimination of bacteria at the source of infection. 
However, infections from blood-borne pathogens are inherently difficult to treat due to their 
spread from an initial site to other locations via the bloodstream; more specifically, the lungs, the 
liver, and the spleen suffer some of the greatest burden in bacteremia [11], [15]–[18]. Upon 
suspicion of sepsis, broad-spectrum antibiotics are administered as the standard of care, along 
with methods to stabilize the patient using intravenous fluids and oxygen, for example. 
Additional stabilization such as mechanical ventilation and kidney dialysis may be necessary for 
severely septic patients. After pathogen identification and antimicrobial susceptibility testing, a 
more specific antibiotic can be used. Administering an effective antibiotic within the first hour 
after hypotension increases the survival rate of patients significantly. However, only half of 
septic patients receive the appropriate therapy within the first six hours; each hour of delay 
decreases the chances of survival by 7.6% [19]. Antimicrobial treatment also has the potential to 
cause harm to patients by eliminating parts of the innate microbiome, especially in the gut, 
leading to various metabolic, immunological, and developmental disorders [20]. Further 
complicating sepsis treatment is the rise of multidrug resistant (MDR) pathogens. Pathogens that 
survive incomplete or ineffective treatment can pass on traits for antimicrobial resistance. These 
strains can then spread rapidly through a population, especially in hospital settings, resulting in 
increasing costs of treatment [21]. An increasing number of MDR strains and the diminishing 
number of new antimicrobials has prompted health organizations to classify combatting 
antimicrobial resistance as high priority [22], [23].   
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1.4. Acinetobacter baumannii infections 
Acinetobacter baumannii, a Gram-negative bacterium, is of particular interest in sepsis 
pathology due to its hardiness: the bacterium can survive under extreme temperature, humidity, 
and pH conditions. As such, A. baumannii is found in a variety of geographic areas, including 
desert climates, and on numerous surfaces, including human skin, mucous membranes, and metal 
hospital bed rails [24]–[26]. Nosocomial A. baumannii infections are of increasing concern due 
to persistent emerging MDR strains, epidemiologically-complex outbreaks, and relatively high 
fatality rates, prompting the Centers for Disease Control and Prevention (CDC) to label MDR 
Acinetobacter spp. as a serious threat [22], [24]–[30]. To combat MDR A. baumannii and other 
MDR Gram-negative bacteria, colistin is the drug of choice. A polycationic decapeptide, colistin 
interacts with the lipopolysaccharides (LPS) in the bacterial outer membrane, destabilizing it and 
leading to cell death [31]. However, colistin was abandoned due to nephrotoxicity, ototoxicity, 
and neurotoxicity concerns; therefore, it is used only as an antibiotic of last resort. Unfortunately, 
strains of A. baumannii are developing resistance to colistin and similar antibiotics, further 
limiting treatment options [32].   
 
1.5. Continuous micromagnetic separation  
Continuous micromagnetic separation is a promising avenue of diagnosis and treatment of 
various bloodborne conditions. With these systems, magnetic nano- or microparticles bind to the 
cells or molecules of interest and are drawn out of flowing fluid with a strong magnetic gradient. 
This isolation can either serve as an isolation/amplification for diagnostic tests or as a treatment 
mechanism for itself. For example, systems have been developed to extract rare circulating 
tumor cells from blood samples [33] or for capture of bacteria from food samples [34]. However, 
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significant focus has been on extracorporeal blood cleansing of pathogens and toxins, similar to 
dialysis. With these devices, blood is withdrawn and mixed with magnetic (usually paramagnetic 
or superparamagnetic) particles, extracted with an extracorporeal magnetic separator, and 
returned to the patient; this has been shown to be efficacious in treating rats challenged with 
large doses of bacteria and endotoxin [35]–[38]. However, no device has been scaled up to treat 
humans as of yet. 
 
1.6. Specific aims 
In this work, the optimization of a microfluidic device for micromagnetic separation is 
outlined. First, the design and fabrication of microfluidic devices are described in Chapter 2. 
These devices are analyzed using computational fluid dynamics in Chapter 3. Then, the 
magnetostatic properties necessary for separation are determined in Chapter 4. In Chapter 5, a 
physically and physiologically-based pharmacokinetic separation model is used to justify the 
various parameters for an extracorporeal separation device. Finally, Chapter 6 discusses the 
potential future directions for extracorporeal separation.   
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CHAPTER 2 
Microfluidic device design and fabrication 
 
2.1. Introduction 
Given the physical size of bacteria and the characteristics of magnetic forces, 
microfluidics techniques are necessary for continuous separation. Microfluidics are loosely 
defined as devices whose characteristic lengths are on the micrometer scale. With such small 
dimensions, extremely precise control of nanoliter or even picoliter volumes is possible. 
Microfluidic devices are also characterized by low Reynolds numbers, indicating a dominance of 
viscous forces over inertial forces. Fluid in this regime is well-characterized, exhibiting 
properties such as laminar flow and diffusion-limited transport. Cells can therefore be readily 
manipulated in this environment without incurring damage.  
The concept of sheath flow is central to magnetic separation design. Since the Reynolds 
number in a microfluidic device is very low (Re < 100), distinct lamellae are formed, with 
minimal advection of species occurring between them. Therefore, biological materials can be 
effectively trapped within their own stream with secondary sheath flows on one or more sides. 
Using the consistent magnetostatic forces generated by two NdFeB magnets (see Chapter 4 for 
details), paramagnetic particles can then be transported out of the primary flow without affecting 
the other constituents (Figure 1). To maximize the surface area for micromagnetic separation 
while maintaining a two-dimensional profile, two dual sheath flow setups were proposed, where 
the primary flow of blood interacts with two sheath flows. The first setup was manufactured 
using SU-8 photolithography and PDMS (polydimethylsiloxane) soft lithography, and finally 
tested using saline flow.  
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Figure 1: Schematic of magnetic separation principles. Infected blood enters the central inlet on the 
left (red) and sheath fluid enters the other inlets (blue). Paramagnetic particles and bound 
bacteria are separated by the magnetic force into the sheath flows (black). 
2.2. Materials and methods 
2.2.1. Microfluidic design 
The microfluidic design was developed using a three-input, three-output framework and 
drafted in Autodesk AutoCAD 2016. Incubated blood enters from a central channel and interacts 
with two sheath flows on either side. These devices focused the three flows into a single main 
channel 300 µm in width and 25 mm in length; the central channel width was varied between 50, 
100, 150, and 200 µm, while each of the sheath flows had a width of half the remainder (i.e., 
125, 100, 75, and 50 µm, respectively). The sheath flows entered the main channel at ± 45° 
(Figure 2).  
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Figure 2: Schematic of microfluidic device, with 0.150mm width for the central channel. Units in 
millimeters. Hatched space indicates where fluid flows. 
2.2.2. SU-8 photolithography  
Masters for the microfluidic devices were fabricated with SU-8 photolithography [39]. 
First, a 4” (1 1 1) monocrystalline silicon wafer was cleaned with acetone and isopropanol while 
spinning at 3000 rpm. The wafer rotation was then stopped and SU-8 2050 photoresist was 
poured onto it. To produce a 50 µm-thick layer, the wafer was spun at 500 rpm for 15 s and then 
accelerated to 2500 rpm for 35 s. During the last 10 s of spinning, any edge bead was removed 
with acetone. The wafer was subsequently baked at 95°C for ten minutes, covered by a 
crystallization dish with an air gap. After baking, a Mylar mask was aligned on the surface of the 
photoresist. The photoresist was exposed to a UV dose of 220 J/cm2; this was achieved by 
measuring the UV lamp’s intensity and calculating the necessary time. The wafer was then baked 
again at 95°C for ten minutes. SU-8 developer was then poured onto the wafer, spun under a 
stream of isopropanol, and dried with nitrogen. For the final hard bake, the wafer was placed 
onto a hotplate with a 60°C/h ramp and a maximum temperature of 150°C, baked at the 
maximum temperature for five minutes, and then cooled on the hotplate. The feature height was 
measured using a contact profilometer.  
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2.2.3. PDMS soft lithography and plasma bonding 
 Once a master was made, devices could be fabricated using PDMS soft lithography [39]. 
Briefly, PDMS and a cross-linking agent were mixed in a 10:1 ratio and poured onto the SU-8 
master in a 6” plastic dish. This was then put in a vacuum desiccator for one minute to remove 
dissolved gasses; resultant bubbles were removed using light application of an air gun. The 
PDMS was then cured at 65°C for three hours. After curing, the area around the devices was cut 
out and divided into individual devices. For assembling a single device, a 25 mm x 75 mm x 1 
mm microscope slide was cleaned with isopropanol and holes were punched into the inlets and 
outlets of the PDMS using a 1.5mm biopsy punch. The sides of the slide and PDMS to be 
bonded were placed face up into a plasma chamber and exposed for 50 s. Promptly after 
removal, the slide and PDMS were pressed firmly together.   
2.2.4. Volumetric flow testing 
 To characterize the flow patterns of the devices, a simple volumetric flow test was 
devised. Tygon tubing (1/16” outer diameter) was used to connect a device to two 10 mL Luer-
Lok syringes. To provide flow to both of the sheath flows, a 25-gauge needle Y-connector 
(Instech Laboratories, Inc.) was used in between the sheath flow syringe and the inlets on the 
device. The device outlets fed into microfuge tubes for collection. Two milliliters of phosphate-
buffered saline (PBS) from each syringe (total of 4mL) was flowed through the device at either 
0.2 mL/min, 0.5 mL/min, or 1.0 mL/min using a syringe pump. The volume of PBS in each of 
the outlet collection tubes was record after flow was completed. Ratios of the central channel 
flow output to the sheath outputs’ combined flow were statistically compared across the varying 
central channel widths and flow rates by two-way ANOVA.  
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Figure 3: Assembled microfluidic device. On the left are the inlets with the Y-connector for the sheath 
flows. The device with two NdFeB magnets is shown on the right. Here, the central flow is shown in red 
and the sheath flows are dyed blue.  
 
2.3. Results and discussion 
The four variations of the microfluidic device were placed in triplicate onto a Mylar mask 
to expedite fabrication (Figure 4). Additional marks were made to the side of the main channel to 
allow for reducing the magnetic separation distance. However, these were not used because the 
PDMS was too thin to resist tearing before plasma treatment. The master resulting from SU-8 
photolithography had a feature height of 68.8 ± 7.4 µm, which was deemed sufficient for initial 
testing (Figure 5); future devices may need more stringent control. PDMS devices were very 
stable, capable of remaining intact with flow rates >2 mL/min, presumably due to their short 
channel length and relatively large channel width. To interpret volumetric flow results, the 
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normalized ratio of volume from the central channel outlet compared to the sum of the sheath 
flows was used; the ideal ratio for all devices was 1, since 2 mL of fluid was flowing through the 
central and sheath channels, respectively. However, none of the devices were able to maintain 
this ratio. All but the 50 µm devices had an average ratio greater than 1, indicating that a 
substantial amount of fluid was exiting out of the center instead of remaining in the sheath flow, 
regardless of flow rate (p > 0.05). Post hoc analysis across the central channel widths shows 
some significance between certain devices, but not amongst all of them (Figure 6). If these 
devices were to be implemented in in situ, this would imply that sheath fluid would be entering 
the patient. As such, these devices were determined to be poor candidates for micromagnetic 
separation.   
 
Figure 4: Mylar mask for fabrication of microfluidic devices. The central channel has a width of, from the 
top right going clockwise, 150 µm, 50 µm, 100 µm, and 200 µm.  
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Figure 5: SU-8 master in PDMS 
 
Figure 6: Results of volumetric flow test for microfluidic devices. Mean ± standard deviation. The 100 
µm devices had a ratio close to 1, while the 50 µm devices had a ratio less than 1 and the others had a 
ratio greater than 1. More fluid was coming out of the central channel in the case of the 150 µm and 200 
µm devices. Roman numerals indicate statistical significance to other devices (numbered left to right). 
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2.4. Conclusion 
 SU-8 photolithography and PDMS soft lithography are the methods of choice for 
microfluidic fabrication, since they are relatively easy and can produce several microfluidic 
devices from a single master. In this chapter, the successful production of microfluidic devices 
intended for micromagnetic separation was demonstrated. However, these devices did not 
properly isolate the sheath flows from the central flow, leading to mixing of fluids upon exit. 
This mixing is less than ideal for a clinical setting, since additional, potentially contaminated 
fluid would return to the patient. More investigation into maintaining sheath flow in a 
microfluidic device needed to be done before any further testing could occur.  
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CHAPTER 3 
Computational fluid dynamics of sheath flow in microfluidic devices 
 
3.1. Introduction 
 Informed design of microfluidics necessitates some exploration into fluid mechanics. The 
velocity, pressure, and other field variables have a great impact on the application of a 
microfluidic device. To solve the governing partial differential equations for fluid flow, 
numerical methods must be used, the preferred of which are finite element methods (FEM). The 
first and second generation microfluidic devices were analyzed for maintenance of a sheath flow 
informed by velocity profiles and mass fluxes.  
 
3.2. Materials and methods 
 ANSYS’ Fluent 17.2 was used for all computational fluid dynamics simulations. A two-
dimensional, steady-state analysis was employed since it is more stable than three-dimensional 
problems and information in the z-direction or over time is not as important given the aspect 
ratios seen in microfluidics. Symmetry conditions were used where possible to reduce 
computational burden.  
 Fluent solves the incompressible two-dimensional Navier-Stokes equation for flow 
 ߩ డడ௧ ܞ + ߩ∇ ⋅ (ܞ ܞ୘) = −∇ܲ + ߤ∇ ⋅ (∇ܞ + ∇ܞ୘) (1) 
in conjunction with the conversation equation,  
 ∇ ⋅ ܞ = 0  (2) 
, where ߩ is the fluid density, ܞ is the fluid velocity, ܲ is the pressure, and ߤ is the fluid’s 
dynamic viscosity. These equations are solved simultaneously using the SIMPLE pressure-based 
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algorithm, a least squares cell based gradient, a second order pressure scheme, and a second 
order upwind momentum scheme. Since the maximum Reynolds number is much less than the 
critical Reynolds number of 2000 (Remax = 400), a laminar model was used. A Newtonian model 
of saline with a constant density of 1.06 g/cm3 and a constant dynamic viscosity of 1.003 x 10-3 
Pa∙s was chosen for the fluid. No-slip boundary conditions were implemented for the walls, 
while a zero gauge pressure was specified at the outlets. The inlets for each of the channels were 
specified with a mass flow rate of 0.0042 g/s based on symmetry conditions. Each device was 
meshed using the uniform setting with maximum face size of 25 µm, 10 µm, 7.5 µm, or 5 µm to 
determine mesh independence of the solutions – that is, that the solution does not depend on the 
mesh – via mass flow rates at the outlets. The solver was run until a relative error of 10-8 between 
iterations was reached.  
Second-generation devices employed a curved design and divided the separation regions 
into two distinct channels. This iteration on the previous generation improves the magnetic flux 
density gradient present in the separation channels, while also ensuring consistent fluidic 
resistance at the flow outlets. All of the inlets and outlets had the same width of 200 µm (Figure 
7). This geometry was analyzed in the same manner as their first-generation counterparts.   
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Figure 7: Schematic of second-generation device. Units in millimeters. Hatched space indicates where 
fluid flows. 
 
3.3. Results and discussion 
 Mesh independence was readily achieved for the 100 µm and 150 µm first-generation 
devices; relative errors were within 3% between the 7.5 µm and 5.0 µm meshes (Figure 8). 
Convergence was more difficult to establish for the 50 µm and 200 µm first-generation devices 
and the second-generation devices because their geometries could not be discretized well by a 
coarse mesh; however, the residuals did decrease to less than 10-3, which is acceptable in some 
scenarios [40]. The ratio of main channel flow to sheath flow shows a trend that agrees with the 
experimental results. However, the magnitudes of the simulated ratios are much greater for 
devices larger than 100 µm and smaller for the 50 µm device (Table 1). This large discrepancy 
may be due to surface tension and three-dimensional effects that are not captured in this two-
dimensional model. Nevertheless, the second-generation device shows some promise, since the 
main-to-sheath flow ratio was approximately 1.31. The velocity profiles of the devices agree 
with the differences in mass flow, with devices with main channel widths larger than 100 µm 
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demonstrating predicted hydrodynamic focusing towards the main outlet, while the 50 µm device 
shows a marked decrease in velocity for the main outlet (Figure 9 - Figure 12). The second-
generation device shows some improvement over the first-generation designs. The mass flow 
ratio is simulated to be 1.31, which is closer to 1 than any of the first-generation devices. 
Furthermore, the velocities for the sheath outlets are much closer to the velocities at the blood 
outlet when compared to the first-generation devices (Figure 13).  
 
Figure 8: Mesh independence study for first-generation devices based on mass flow rate through left 
sheath outlet. 5 µm mesh size omitted from 50 µm and 200 µm devices due to failure to generate mesh. 
Less than 3% variation is seen between the finest meshes for the 100 µm and 150 µm devices. 
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Table 1: Experimental versus simulated mass flow ratios for first-generation devices. 
Central channel width (µm) Experimental mass flow ratio Simulated mass flow ratio 
50 0.42 0.13 
100 1.35 1.98 
150 3.45 15.55 
200 5.09 116.08 
 
 
Figure 9: Velocity profile at outlet for 50 µm device. 
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Figure 10: Velocity profile at outlet for 100 µm device. 
 
Figure 11: Velocity profile at outlet for 150 µm device. 
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Figure 12: Velocity profile at outlet for 200 µm device. 
 
Figure 13: Velocity profile at outlet for second-generation device. 
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3.4. Conclusion 
 Computational fluid dynamics is a powerful analysis tool for microfluidics. It can make 
visible properties that are not readily apparent by other techniques and can inform design and 
redesign. The first-generation devices previously described are ill-suited for magnetic separation 
because they have a tendency to focus flow to the largest outlet rather than maintaining distinct 
lamellae. Additional investigation into this modeling could be carried out. For example, three-
dimensional effects can be incorporated into fluidics models, also this tends to be more 
computationally expensive. Additionally, various models for blood on this length scale exist and 
should be taken into consideration when designing blood-centric microfluidic devices.  
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CHAPTER 4 
Magnetostatic modeling of separation device 
 
Text adapted from:  
Petty Valenzuela, Stephen N., Sinead E. Miller, Charleson S. Bell, Todd D. Giorgio. 
“Optimization of micromagnetic separation for bacteremia treatment.” 2nd International 
Conference on Nanomedicine, Drug Delivery, and Tissue Engineering, Barcelona, Spain, 2017. 
 
4.1. Introduction 
 To calculate the motion and thus the separation of paramagnetic particles, the magnetic 
field used must be quantitatively described. Specifically, the force on paramagnetic particles is 
directly proportional to the magnetic flux density gradient, represented here as |∇ܤଶ|. The partial 
differential equations (PDEs) that describe the magnetic field and magnetic flux density cannot 
be solved analytically if complex geometries are involved, such as the field produced by multiple 
magnets. In this chapter, the magnetic field to be used in the separation device is explored in 
various magnet configurations to optimize the separation of paramagnetic particles.  
 
4.2. Materials and Methods 
 The program FEMM 4.2 was used to calculate the magnetic field, ۶, and flux density, ۰, 
of the magnets. The general time-invariant magnetostatic problem has the governing equations  
   ∇×۶ = ۸  (3) 
   ∇ ∙ ۰ = 0 (4) 
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where ۸ is the current density. The constitutive equation relating the field to the flux density by 
the permeability, ߤ,  
   ۰ = ߤ۶ (5) 
must be used for each linear material in the domain. FEMM solves these equations using a 
magnetic vector potential approach, defining the magnetic flux density in terms of a vector 
potential, ۯ,  
   ۰ = ∇×ۯ (6) 
This allows the magnetic field governing equation to be rewritten as  
   ∇× ቀଵఓ ∇×ۯቁ = ۸ (7) 
and ۯ can be solved for using finite element analysis (FEA). ۰ and ۶ can then be derived from 
ۯ.  
 Two rectangular neodymium (NdFeB) magnets (K&J Magnetics, BX04X0, Grade N42 
NdFeB, 1" x 1/4" x 1" thick, ߤ௥ = 1.05, ܪ௖ =  1006582 A/m) were simulated via FEA in an 
attracting configuration with a separation distance of 25mm, equivalent to the width of the 
device. The poles of these magnets are located on the 1/4” thick sides rather than on the square 
faces, making them ideal for a low-profile separator. The flux density field across the gap in the 
y-direction was obtained and then differentiated in Matlab 2015a to determine the magnetic flux 
density gradient, represented here as |∇ܤଶ|.  
 
4.3. Results and discussion 
 The domain near two rectangular NdFeB magnets was simulated with 4574 nodes and 
8721 elements via FEA. The calculated two-dimensional magnetic flux density is comparable to 
the manufacturer’s documentation [41] (Figure 14). A parabolic profile with a maximum flux 
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density of 0.521T and a minimum field strength of 0.360T across the channel was estimated 
(Figure 15). The magnetic flux density gradient ranges from approximately -20 T2/m to 20 T2/m; 
discretization error from differentiation resulted in a non-smooth curve (Figure 16). At the 
location of the microfluidic channels, 2.1mm from the center of the space between the magnets, 
the magnetic flux density gradient was calculated to be 4.7 T2/m. With this magnetic flux field, a 
linear magnetic flux density gradient can be established to ensure consistent separation of 
magnetic complexes.  
 
Figure 14: Magnetic flux density plotted over domain. Fluid flow is in the x-direction.  
y 
x 
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Figure 15: Magnetic flux density in vertical direction. 
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Figure 16: Magnetic flux density gradient in vertical direction. Regression line (red): |∇ܤଶ| =
1.8182 ୘మ୫ ௬୫୫ , R2 = 0.9872. 
4.4. Conclusion 
 Magnetostatic modeling of the two-magnet configuration produces a parabolic magnetic 
flux profile and a linear magnetic flux density gradient. At the point halfway between the two 
magnets, the magnetic flux density gradient is at or near zero, meaning microfluidic channels for 
separation must be offset from the center to achieve efficient separation. A further advantage to 
this linear profile is that magnetic particles should be drawn outward, regardless of which side of 
the device the particle is on.   
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CHAPTER 5 
Physiologically-based pharmacokinetic model with physically-based separation model 
 
Text adapted from:  
Petty Valenzuela, Stephen N., Sinead E. Miller, Charleson S. Bell, Todd D. Giorgio. 
“Optimization of micromagnetic separation for bacteremia treatment.” 2nd International 
Conference on Nanomedicine, Drug Delivery, and Tissue Engineering, Barcelona, Spain, 2017. 
 
5.1. Introduction 
 The removal of bacteria from the various infected organs can be modeled as a clearance 
mechanism, lending credence to a multi-compartmental physiologically-based pharmacokinetic 
(PBPK) model. PBPK models of bacterial infection have been in existence since at least 
Cheewatrakoolpong et al.’s two-compartmental murine model [42]. Miller et al. were the first to 
incorporate an extracorporeal pathogen removal device into an infection model [16]. A magnetic 
separation model was developed by Kang et al. for their device, interrogating the role of the 
radius of their magnetic beads in separation efficiency from whole blood [38]. Combining these 
models allows for better understanding of the pharmacokinetics of extracorporeal pathogen 
removal via magnetic beads and can inform the selection of bead radius, incubation times, and 
device flow rates.  
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5.2. Materials and Methods 
5.2.1. Analytic model of magnetic separation 
 The binding efficiency of particles to A. baumannii was estimated. As discussed by Kang 
et al., the concentration of bound bacteria, ܿ଴, as a function of microsphere radius and incubation 
time can be expressed as 
  ܿ଴(ݎ௕, ݐ௜௡௖) = ܿ଴௜௡ exp(−ܿ௘(݇ௗ + ݇௦௛௘௔௥)ܾݐ௜௡௖) (8) 
where ܿ଴௜௡ is the initial concentration of bacteria; ܿ௘ is an empirical constant to account for 
changes in binding efficiency in biologically relevant fluids; ݇ௗ and ݇௦௛௘௔௥ are the collision rate 
constants of diffusion and shear, given respectively by 
  ݇ௗ = ଶ௥೎௞ಳ்ଷఎ௥್  (9) 
  ݇௦௛௘ = ߨߛሶ(ݎ௕ + ݎ௖)ଷ  (10) 
with Boltzmann’s constant, ݇஻, the ambient temperature, ܶ, the viscosity of blood, ߟ, the 
spherical radius of the cell,  ݎ௖, and the empirically determined shear rate, ߛሶ , held constant; ܾ as 
the concentration of microspheres calculated relative to a given concentration of ݎ௕ = 500 nm 
microspheres by 
  ܾ = ܾହ଴଴ ୬୫ ቀହ଴଴ ୬୫௥್ ቁ
ଷ  (11) 
and ݐ௜௡௖ as the incubation time. The overall binding efficiency, ݔ, is therefore estimated as  
  ݔ(ݎ௕ , ݐ௜௡௖) = 1 − ௖బ(௥್,௧೔೙೎)௖బ೔೙ = 1 − exp(−ܿ௘(݇ௗ + ݇௦௛௘௔௥)ܾݐ௜௡௖)  (12) 
After incubation, the microspheres and microsphere-bacteria complexes are separated out via the 
magnetophoretic force,  
  ܨ௠௔௚ = ܰ ସగ௥್యଷ ఞೡଶఓబ |∇ܤଶ|  (13) 
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with the constants ߤ଴, the vacuum magnetic permeability; ߯௩, the volumetric susceptibility of the 
microspheres; and |ߘܤଶ|, the magnetic flux density gradient. ܰ is the number of microspheres 
bound to a bacterium and is estimated by  
  ܰ(ݎ௕) = 4ߩ ቀ௥೎௥್ቁ
ଶ  (14) 
Here, ߩ refers to the estimated proportion of the cell surface covered by microspheres.  
 Opposing the magnetophoretic force is the drag force in terms of the magnetophoretic 
velocity, ݒ௠௔௚, given by Stokes flow  
  ܨௗ௥௔௚ = 6ߨݎ௡ߟݒ௠௔௚  (15) 
where ݎ௡ is the effective hydraulic radius of a microsphere-bacterium complex given by  
  ݎ௡ = ටݎ௖ଷ + ܰݎ௕ଷయ  (16) 
Solving ܨ௠௔௚ = ܨௗ௥௔௚ for ݒ௠௔௚ under the assumption of force equilibrium, the magnetophoretic 
velocity of the complexes is equal to  
  ݒ௠௔௚ = ே௥್యఞೡ|∇஻మ|ଽఎఓబ௥೙  (17) 
Therefore, the magnetic separation time across the width of the channel, ݓ, can be calculated as  
  ݐ௠௔௚ = ݓ/ݒ௠௔௚ (18) 
 Assuming steady flow in the separation channels, the average velocity of a complex is 
given by  
  ݒ௙തതത = ொಶ௡஺ (19) 
ܳா being the volumetric flow rate through the entire device, ݊ being the number of channels, and 
ܣ = ℎݓ being the rectangular cross-sectional area of a channel with height ℎ and width ݓ. The 
residence time in the channel with length ݈ can be calculated as  
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  ݐ௥௘௦ = ݈/ݒ௙തതത (20) 
The magnetic separation efficiency ݉ is then estimated by  
   ݉(ݎ௕, ܳா) = ൝
௧ೝ೐ೞ௧೘ೌ೒ , ݐ௥௘௦ < ݐ௠௔௚1 , ݐ௥௘௦ ≥ ݐ௠௔௚  (21a) 
   = ቐ
ସ௡௛௟ఘ௥್௥೎మఞೡห∇஻మห
ଽொಶఎఓబ൫௥೎యାସఘ௥್௥೎మ൯భ/య , ݐ௥௘௦ < ݐ௠௔௚1 , ݐ௥௘௦ ≥ ݐ௠௔௚ (19b) 
 After the incubation and separation stages, the overall fraction of bacteria removed can be 
expressed as  
  ݂(ݎ௕, ܳா , ݐ௜௡௖) = ݔ(ݎ௕ , ݐ௜௡௖) ∗ ݉(ݎ௕, ܳா) (22) 
Table 2 lists the physical constants and parameters used for all of the simulations. The device-
specific parameters (width, height, length, and number of channels) are based on the second-
generation microfluidic design detailed in Chapter 2.   
 
Table 2: Constants for magnetic separation efficiency calculations. Magnetic flux density gradient is as 
determined in magnetostatic FEA.
Parameter Value and units Parameter Value and units 
ܿ଴௜௡ 107 CFU/mL ߯௩ 3.5 
ܿ௘ 3.7 x 10-4 ߩ 0.5 
ܶ 300 K ݓ 1 x 10-4 m 
ߟ 4.0 x 10-3 kg m-1 s-1 ݊ 2 
ݎ௖ 0.5 x 10-6 m ℎ 5 x 10-5 m 
ߛሶ  1.0186 s-1 ݈ 2.5 x 10-2 m 
ܾହ଴଴ ୬୫ 0.0025 kg m-3 |∇ܤଶ| 4.7 T2/m 
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5.2.2. Multi-compartment physiologically-based pharmacokinetic infection model  
 The fractional magnetic separation from Equation 22 factors into the five-compartment 
PBPK model of infection diagrammed in Fig. 1 and detailed in Equations 23-27. Each 
physiologic compartment has its own associated growth rate, ܩ௜, a blood volume, ௜ܸ, blood flow 
rate, ܳ௜, and a partition coefficient to bacteria, p௜ (Table 3). The transport of bacteria between 
compartments is represented by the arrows in Figure 17. The most significant modification from 
the model published by Miller et al.[16] is the removal of the return pathway from the device to 
the blood; here, the assumption is that any bacteria removed by the device has no path of reentry 
into the circulatory system. 
 
Figure 17: Diagram of infection compartmental model. Arrows indicate blood flow between the 
compartments. Letters in parentheses indicate symbols used for the compartmental concentrations in the 
equations. 
  ௗ௅ௗ௧ = ܩ௅ܮ + ொಽ௏ಽ ܤ − ொಽ୮ಽ௏ಽ ܮ (23) 
  ௗௌௗ௧ = ܩௌܵ + ொೄ௏ೄ ܤ − ொೄ୮ೄ௏ೄ ܵ  (24) 
  ௗுௗ௧ = ܩுܪ + ொಹ௏ಹ ܤ + ொೄ୮ೄ௏ೄ ܵ − ொಹାொೄ୮ಹ௏ಹ ܪ  (25) 
  ௗ஻ௗ௧ = ܩ஻ܤ + ொಹାொೄ୮ಹ௏ಹ ܪ + ொಽ୮ಽ௏ಽ ܮ – ቀொಽ௏ಽ + ொೄ௏ೄ + ொಹ௏ಹ + ݂(ݎ௕ , ܳா , ݐ௜௡௖) ொಶ௏ಶቁ ܤ  (26) 
  ௗாௗ௧ = ݂(ݎ௕ , ܳா , ݐ௜௡௖) ொಶ௏ಶ ܤ (27) 
Blood (B) Liver (H) Lungs (L) 
Spleen (S) 
Device (E) 
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 Six different infection and treatment scenarios were then simulated using the coupled 
models: a non-immunocompromised human, an immunocompromised human, an 
immunocompromised human with antibiotic administration, and using the extracorporeal device 
with the three previous scenarios. A simulated bolus of 107 CFU/mL of A. baumannii was 
injected into the lung compartment and allowed to proliferate in the system for ten hours. After 
incubating the blood with the colistinated magnetic microspheres for ݐ௜௡௖ = 5 min, the 
extracorporeal device was linked into the system and ran for 96 hours. To determine the efficacy 
of treatment, the area under the curve (AUC) via trapezoidal integration in each of the 
compartments was compared across flow rates and microsphere radii. As a quantifiable criterion, 
the time to go below a threshold of 1 CFU/mL in the bloodstream was also examined [16].  
 Matlab 2015a’s 4th-order Runge-Kutta solver was used to calculate an approximate 
solution to the system of differential equations (Appendix).  
 
Table 3: Parameters for PBPK model of A. baumannii infection.
 IC = immunocompromised 
AB = antibiotic + immunocompromised 
ܘ࢏ ࡳ࢏ (h-1) 
Compartment ࡽ࢏ (m3 
h-1) 
ࢂ࢏ (m3 h-1) Normal IC Normal IC AB 
Lungs 0.08995 4.50 x 10-4 93 3 -1.74 0.21 -0.24 
Spleen 0.01501 2.09 x 10-4 59 28 -0.14 0.14 -0.07 
Liver 0.0483 1.56 x 10-3 749 79 -0.10 0.10 -0.18 
Blood N/A N/A N/A N/A -0.17 0.08 -0.05 
Device variable 2.5 x 10-10 1 1 N/A N/A N/A 
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5.3. Results and discussion 
 Using the magnetic flux density gradient from the previous magnetostatic simulation, the 
magnetic separation of microsphere-bacteria complexes was modeled for microspheres with radii 
from 25nm to 500nm, which correspond to common paramagnetic microspheres. The device 
flow rate was varied over the typical range of microfluidic flow rates, 0.01mL/min to 
1.5mL/min. Infection metrics, including maximum bacterial load, time to threshold, and area 
under the curve, did not change significantly with microsphere radius or flow rate. The standard 
deviation of any metric is at least two orders of magnitude smaller than the mean (Table 4). 
Bacterial loads do not change significantly with the incorporation of the extracorporeal device, 
despite quantifiable bacterial capture in comparison with the absence of extracorporeal bacterial 
separation (Figure 18).  
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Table 4: Infection metric statistics across parameter space. Mean ± standard deviation. N/A here indicates 
that the compartment’s bacterial load never went below 1 CFU/mL.
 Compartment Max. load (CFU/mL) Time to 
threshold (h) 
AUC (CFU/mL * h) 
Non
-im
mu
noc
omp
rom
ised
 Lungs 1.32 x 104 ± 6.82 x 10-10 75.97 ± 0.001 1.06 x 105 ± 8.09 x 100 
Spleen 1.45 x 104 ± 4.02 x 10-10 76.72 ± 0.002 1.16 x 105 ± 8.33 x 100 
Liver 8.66 x 105 ± 5.47 x 10-9 N/A 6.93 x 106 ± 9.73 x 101 
Blood 2.49 x 102 ± 2.63 x 10-2 44.17 ± 0.004 1.99 x 103 ± 1.57 x 10-1 
Imm
uno
com
pro
mis
ed 
Lungs 1.02 x 1010 ± 5.36 x 107 N/A 9.58 x 1010 ± 4.57 x 108 
Spleen 9.61 x 1010 ± 5.04 x 107 N/A 9.04 x 1011 ± 4.29 x 109 
Liver 6.76 x 1011 ± 3.48 x 109 N/A 6.36 x 1012 ± 2.96 x 1010 
Blood 3.39 x 109 ± 1.78 x 107 N/A 3.19 x 1010 ± 1.52 x 108 
Ant
ibio
tic +
 
imm
uno
com
pro
mis
ed 
Lungs 2.48 x 104 ± 5.71 x 10-10 60.76 ± 0.02 1.49 x 105 ± 6.44 x 101 
Spleen 2.41 x 105 ± 4.83 x 10-9 74.41 ± 0.03 1.44 x 106 ± 5.87 x 102 
Liver 1.66 x 104 ± 5.26 x 10-10 86.00 ± 0.03 9.94 x 106 ± 3.13 x 103 
Blood 8.27 x 103 ± 1.55 x 10-10 54.17 ± 0.02 4.96 x 104 ± 2.15 x 101 
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Figure 18: Log-log plots of bacterial load over time for all compartments with ݎ௕ = 75 nm and ܳா = 0.1 
mL/min. From top to bottom: non-immunocompromised (a, b), immunocompromised (c, d), and 
immunocompromised with antibiotic (e, f). Left (a,c,e): without device separation; right (b,d,f): with 
device separation.   
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5.4. Conclusion 
 Incorporating a physically-based magnetic separation efficiency model into a 
physiologically-based pharmacokinetic model allows for a better understanding of the efficacy of 
a magnetics-based extracorporeal separation device. Using the model and parameters outlined, 
clinical outcomes would most likely not improve, since bacterial load metrics were not 
significantly changed by magnetic separation of bacteria from blood under any microsphere 
radius or device flow rate evaluated. High-throughput, high-capture devices will be essential for 
there to be any improvement of patient outcomes. Applying constrained nonlinear optimization 
to this problem with additional variables, such as device height and length, could better inform 
design by reducing the computational burden in exploring the feasible parameter space. 
  
 37
CHAPTER 6 
Conclusions and future directions 
 
 Bacteremia and bacterial sepsis are a major public health concern due to the increasing 
number of cases of antibiotic resistance, rendering conventional treatment methods ineffective. 
To combat this emergence, the challenges of rapid diagnosis and treatment must be met. 
Extracorporeal bacterial separation methods show promise as a means to identify pathogens and 
cleanse blood of bacteria, reducing the overall bacterial load. Micromagnetic separation utilizes 
paramagnetic microparticles to transport bound bacteria from a primary fluid flow to a secondary 
sheath flow. To enable efficient separation of these particles, microfluidics must be used.  
 In this work, microfluidic devices for magnetic separation were fabricated using SU-8 
photolithography and soft lithography and then characterized using volumetric flow 
measurements. These results were confirmed using computational fluid dynamics, which also 
improved understanding of the flow behavior within the devices. Additional modeling of 
micromagnetic separation using magnetostatic finite element analysis and a physiologically-
based pharmacokinetic model provided further information for design considerations.  
Based on the results of the mathematical modeling, a single device is insufficient to 
impact clinical outcomes in patients with bacteremia. Although bacteria could be removed via 
magnetic separation, the throughput and capacity of a device must be enough to impact the 
course of bacteremia in large living systems such as humans. Parallelization of several magnetic 
separation devices could potentially achieve the necessary thresholds; however, this drastically 
increases the complexity of the separation. Magnetic fields between devices would interact, 
potentially disrupting the consistent gradient observed in the two-magnet setup. Additionally, 
 38
flowing blood through microfluidic channels increases cellular activity and risks coagulation. 
Furthermore, any uncaptured magnetic microparticles would return to the patient, prompting 
toxicity concerns. Although micromagnetic separation has the potential to be a method of 
extracorporeal bacterial separation, many challenges must be overcome. Nevertheless, 
micromagnetic separation may be useful in diagnostic methods, since binding of specific and 
relevant moieties can be engineered for particles.  
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Appendix A: Infection model Matlab code 
% Measured in CFU/m^3 c_0_in = 1e7 / 1e-6;  
  
% Must use SI units (m, s, etc.) w = 100e-6;   h = 100e-6;  n = 20000;  Q = 1.667e-8*[0.01:0.01:0.1,0.2:0.1:1.5]; l = 0.025;  a = w * h; % cross sectional area of a single channel of device 
  
% Binding kinetics b_500 = 0.0025; % concentration of 500nm magnetic particles (kg/m^3) 
  
r_b = (25:5:500)*10^-9; 
  
r_c = 0.5 * 10^-6; % spherical radius of A. baumannii bacteria (m) 
  
b = b_500*(((5*10^-7)./r_b).^3); %b = concentration of magnetic beads. 5*10^-7 m = nm to m = control bead radius 
  
k_B = 1.38*10^-23; %Boltzmann's constant in kg*m^2*s^-2*K^-1 
  
T = 300; %temperature in kelvin 
  
n_b = 4 * (10^-3); %viscosity of blood in <N*s*m^-2> 
  
%k_d = collision rate constant of diffusion 
  
k_d_b = (2 * r_c * k_B * T)./(3 * n_b .* r_b); %blood 
  
r_t = 0.005; % radius of 1.5 mL centrifuge tube (m) 
  
Q_shear = 1e-7; %approximate volumetric flow rate  (m^3/s) in tube 
  
gamma = (4 * Q_shear)/(pi * (r_t^3)); 
  
%k_shear = collision rate constant of shear 
  
k_shear = pi * gamma .* (r_b + r_c).^3; 
  
  
p = 0.5; %fraction of bacteria surface area that can be covered by NPs 
  
N = 4 * p * ((r_c./r_b).^2); % N = number of NPs boud to single bacteria 
  
delB2 = 4.7; %B = magnetic field intensity in <T^2/m> 
  
x_v = 3.5; %Volumetric susceptibility of NPs 
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u_o = (4 * pi) * 10^-7; %magnetic permeability of a vacuum in <T*m*(A^-1)> 
  
r_n = ((r_c.^3) + N .* (r_b.^3)).^(1/3); % Effective hydraulic radius  
  
%v_mag = magnetophoretic velocity of bacteria labeled with magnetic NPs (m/s) 
  
v_mag_n = ((r_b.^3) .* N .* x_v .* delB2)./(9 * r_n * n_b * u_o); % blood v_mag_b = ((r_b.^2) .* x_v .* delB2)./(9 * n_b * u_o); 
  
t_mag_n = w./v_mag_n; % bound bacteria t_mag_b = w./v_mag_b; % beads only 
  
t_2 = 5*60; % incubation time in seconds  c_e_b = 3.7e-4;  c_o_b = (c_0_in) .* exp(-1 * c_e_b * (k_d_b + k_shear) .* b .* t_2);%blood 
  
h_n = zeros(length(Q),length(r_b));  g_n = zeros(length(Q),length(r_b));  g_b = zeros(length(Q),length(r_b)); f_b = zeros(length(Q),length(r_b));  
  
thresh = 1; % CFU/mL 
  
Lend = zeros(length(Q),length(r_b));  Send = zeros(length(Q),length(r_b));  Hend = zeros(length(Q),length(r_b));  Bend = zeros(length(Q),length(r_b));  Eend = zeros(length(Q),length(r_b));  
  
Lmax = zeros(length(Q),length(r_b));  Smax = zeros(length(Q),length(r_b));  Hmax = zeros(length(Q),length(r_b));  Bmax = zeros(length(Q),length(r_b));  Emax = zeros(length(Q),length(r_b));  
  
LAUC = zeros(length(Q),length(r_b));  SAUC = zeros(length(Q),length(r_b));  HAUC = zeros(length(Q),length(r_b));  BAUC = zeros(length(Q),length(r_b));  EAUC = zeros(length(Q),length(r_b));  
  
Lthresh = zeros(length(Q),length(r_b));  Sthresh = zeros(length(Q),length(r_b));  Hthresh = zeros(length(Q),length(r_b));  Bthresh = zeros(length(Q),length(r_b));  
  
status = 1;  
  
t_i = 10;  [t0,y0] = ode45(@(t,y) KP_Human_infection_model_v2(t,y,[0 w h n l status 0]),[0 t_i],[c_0_in/1e6 0 0 0 0]); y00 = y0(end,:); % Bacteria levels ten hours after inoculation  
  
t_h = 96; % hours of treatment  
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for j = 1:length(Q)     %v_l = linear average velocity of bacteria labeled with MNPs flowing 
  
    %through 1 of the n channels of the device (m/s) 
  
    v_l = Q(j)/(n * a); 
  
    %t_res = characteristic residence time in a channel (s) 
  
    t_res = l/v_l; 
  
    %t_mag = time required for the complex to magnetically migrate from 
  
    %position A to position B (s) 
  
    for k = 1:length(r_b)         if (t_res >= t_mag_n(k))             g_n(j,k) = 1;              h_n(j,k) = (1 - exp(-c_e_b * (k_d_b(k) + k_shear(k)) .* b(k) .* c_o_b(k) .* t_2));              f_b(j,k) = h_n(j,k);          elseif (t_res < t_mag_n(k))             g_n(j,k) = t_res/t_mag_n(k);              h_n(j,k) = (t_res .* ((1 - exp(-c_e_b * (k_d_b(k) + k_shear(k)) .* b(k) .* c_o_b(k) .* t_2)))) ./t_mag_n(k);              f_b(j,k) = h_n(j,k)/g_n(j,k);          end     end 
  
    g_b(j,:) = t_res./t_mag_b;  
     
    parfor (k = 1:length(r_n), 4)         [j,k]         f = h_n(j,k); % fraction of bacteria captured         [tjk,yjk] = ode45(@(t,y) KP_Human_infection_model_v2(t,y,[Q(j) w h n l status f]),[0 t_h],y00); 
  
        Lend(j,k) = yjk(end,1);          Send(j,k) = yjk(end,2);          Hend(j,k) = yjk(end,3);          Bend(j,k) = yjk(end,4);          Eend(j,k) = yjk(end,5);  
  
        Lmax(j,k) = max(yjk(:,1));          Smax(j,k) = max(yjk(:,2));          Hmax(j,k) = max(yjk(:,3));          Bmax(j,k) = max(yjk(:,4));          Emax(j,k) = max(yjk(:,5));   
         
        LAUC(j,k) = trapz(tjk,yjk(:,1));          SAUC(j,k) = trapz(tjk,yjk(:,2));         HAUC(j,k) = trapz(tjk,yjk(:,3));          BAUC(j,k) = trapz(tjk,yjk(:,4));          EAUC(j,k) = trapz(tjk,yjk(:,5));   
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        if size(find(yjk(:,1)<=thresh),1) ~= 0             Lthresh(j,k) = tjk(find(yjk(:,1)<=thresh,1));          end         if size(find(yjk(:,2)<=thresh),1) ~= 0             Sthresh(j,k) = tjk(find(yjk(:,2)<=thresh,1));          end         if size(find(yjk(:,3)<=thresh),1) ~= 0             Hthresh(j,k) = tjk(find(yjk(:,3)<=thresh,1));          end         if size(find(yjk(:,4)<=thresh),1) ~= 0             Bthresh(j,k) = tjk(find(yjk(:,4)<=thresh,1));          end     end end      
  
figure(1);  plot(r_b,f_b(1,:));  title('Binding efficiency'); figure(2);  surf(r_b,Q/1.667e-8,g_n);  title('Magnetic separation efficiency of complexes');  figure(3);  surf(r_b,Q/1.667e-8,h_n);  title('Overall separation efficiency');  figure(4); surf(r_b,Q/1.667e-8,g_b);  title('Magnetic separation of microspheres');  
  
figure(5); surf(r_b,Q/1.667e-8,Lend);  title('Bacterial load in lungs after treatment');  figure(6); surf(r_b,Q/1.667e-8,Send);  title('Bacterial load in spleen after treatment');  figure(7); surf(r_b,Q/1.667e-8,Hend);  title('Bacterial load in liver after treatment');  figure(8); surf(r_b,Q/1.667e-8,Bend);  title('Bacterial load in blood after treatment');  figure(9); surf(r_b,Q/1.667e-8,Eend);  title('Bacterial load in device after treatment');  
  
figure(10); surf(r_b,Q/1.667e-8,Lmax);  title('Maximum bacterial load in lungs');  figure(11); surf(r_b,Q/1.667e-8,Smax);  title('Maximum bacterial load in spleen');  figure(12); surf(r_b,Q/1.667e-8,Hmax);  title('Maximum bacterial load in liver');  figure(13); surf(r_b,Q/1.667e-8,Bmax);  
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title('Maximum bacterial load in blood');  figure(14); surf(r_b,Q/1.667e-8,Emax);  title('Maximum bacterial load in device');  
  
figure(15); surf(r_b,Q/1.667e-8,Lthresh);  title('Time to threshold in lungs');  figure(16); surf(r_b,Q/1.667e-8,Sthresh);  title('Time to threshold in spleen');  figure(17); surf(r_b,Q/1.667e-8,Hthresh);  title('Time to threshold in liver');  figure(18); surf(r_b,Q/1.667e-8,Bthresh);  title('Time to threshold in blood');  
  
[t1,y1] = ode45(@(t,y) KP_Human_infection_model_v2(t,y,[0 w h n l status 0]),[0 t_h],y00); figure(19);  loglog(t1,y1(:,1),'b','LineWidth',3);  hold on;  loglog(t1,y1(:,2),'Color',[1 0 1],'LineWidth',3);  loglog(t1,y1(:,3),'Color',[1 0.5 0],'LineWidth',3);  loglog(t1,y1(:,4),'r','LineWidth',3);  loglog(t1,y1(:,5),'Color',[34 149 34]/255,'LineWidth',3);  hold off;  xlim([1 100]); ylim([1 1e10]);  xlabel('Time (h)','FontSize',22);  ylabel('Bacterial load (CFU/mL)','FontSize',22);  
  
[t2,y2] = ode45(@(t,y) KP_Human_infection_model_v2(t,y,[Q(10) w h n l status h_n(11,10)]),[0 t_h],y00); figure(20);  loglog(t2,y2(:,1),'b','LineWidth',3);  hold on;  loglog(t2,y2(:,2),'Color',[1 0 1],'LineWidth',3);  loglog(t2,y2(:,3),'Color',[1 0.5 0],'LineWidth',3);  loglog(t2,y2(:,4),'r','LineWidth',3);  loglog(t2,y2(:,5),'Color',[34 149 34]/255,'LineWidth',3);  hold off;  xlim([1 100]); ylim([1 1e10]);  xlabel('Time (h)','FontSize',22);  ylabel('Bacterial load (CFU/mL)','FontSize',22);    
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Appendix B: PBPK differential equations Matlab function 
 function dydt = KP_Human_infection_model_v2(t,y,PARAM) %#ok<INUSL> % PARAM(1) = total flow rate through device % PARAM(2) = channel width % PARAM(3) = channel height % PARAM(4) = number of channels % PARAM(5) = channel length % PARAM(6) = immuno status  % PARAM(7) = fractional separation 
  
% L = lung % S = spleen % H = liver % B = blood % E = extracorpoeral device 
  
Q_E = PARAM(1)*3600; % conversion to m^3/h w = PARAM(2); h = PARAM(3);  n = PARAM(4);  l = PARAM(5);  
  
% Growth rate (1/h) if PARAM(6) == 0 % immunocompromised      G_L = 0.21;     G_S = 0.14;      G_H = 0.10;      G_B = 0.08;  elseif PARAM(6) == 1 % immunocompromised with antibiotic     G_L = -0.24;     G_S = -0.07;      G_H = -0.18;       G_B = -0.05; elseif PARAM(6) == 2 % non-immunocompromised     G_L = -1.74;     G_S = -0.14;      G_H = -0.10;      G_B = -0.17; end 
  
%V = blood volume (m^3) 
  
V_L = 450e-6; 
  
V_S = 2.09e-4;  
  
V_H = 0.00156; % 9 percent of total blood volume 
  
V_E = n * w * h * l;  
  
%Q = rate of blood flow to each compartment (m^3/h) 
  
Q_L = 0.08995; 
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Q_S = 0.01501; 
  
Q_H = 0.0483; 
  
% Partition coefficients (dimless) if PARAM(6) == 0 || PARAM(6) == 1     p_L = 3;     p_S = 28;      p_H = 79;  elseif PARAM(6) == 2     p_L = 93;     p_S = 59;      p_H = 749;  end 
  
  
% magnetic separation 
  
L = y(1); 
  
S = y(2); 
  
H = y(3); 
  
B = y(4); 
  
E = y(5); 
  
f = PARAM(7);  
  
% magnetic separation 
  
dydt = zeros(size(y)); 
  
dydt(1) = (G_L*L) + ((Q_L/V_L)*B) - ((Q_L/(V_L*p_L))*L); 
  
dydt(2) = (G_S*S) + ((Q_S/V_S)*B) - ((Q_S/(V_S*p_S))*S);  
  
dydt(3) = (G_H*H) + ((Q_H/V_H)*B) + ((Q_S/(V_S*p_S))*S) - (((Q_H+Q_S)/(V_H*p_H))*H);  
  
dydt(4) = (G_B*B) + (((Q_H+Q_S)/(V_H*p_H))*H) + ((Q_L/(V_L*p_L))*L) - (((Q_H/V_H) + (Q_S/V_S) + (Q_L/V_L)+ (f * (Q_E/V_E)))*B);  
  
dydt(5) = ((Q_E/(V_E)) .* B .* f);      
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